CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE.
biomarker
hepatocellular carcinoma
immune profiling
transarterial chemoembolization
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
20 03 2023
20 03 2023
Historique:
received:
12
12
2022
revised:
14
03
2023
accepted:
16
03
2023
medline:
30
3
2023
entrez:
28
3
2023
pubmed:
29
3
2023
Statut:
epublish
Résumé
Distinct immune patterns of hepatocellular carcinoma (HCC) may have prognostic implications in the response to transarterial chemoembolization (TACE). Thus, we aimed to exploratively analyze tumor tissue of HCC patients who do or do not respond to TACE, and to identify novel prognostic biomarkers predictive of response to TACE. We retrospectively included 15 HCC patients who had three consecutive TACE between January 2019 and November 2019. Eight patients had a response while seven patients had no response to TACE. All patients had measurable disease according to mRECIST. Corresponding tumor tissue samples were processed for differential expression profiling using NanoString nCounter
Identifiants
pubmed: 36975480
pii: curroncol30030267
doi: 10.3390/curroncol30030267
pmc: PMC10046993
doi:
Substances chimiques
Chemokine CXCL1
0
Chemokine CXCL6
0
CXCL1 protein, human
0
CXCL6 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3516-3528Références
Hepat Oncol. 2020 Mar 18;7(1):HEP18
pubmed: 32273976
J Hepatol. 2019 May;70(5):893-903
pubmed: 30660709
Ann Oncol. 2013 Oct;24(10):2565-2570
pubmed: 23857958
Brain Pathol. 2021 May;31(3):e12957
pubmed: 34043263
J Clin Gastroenterol. 2017 Oct;51(9):845-849
pubmed: 28877082
Cell Physiol Biochem. 2014;34(5):1536-46
pubmed: 25323032
Liver Int. 2016 Jan;36(1):100-7
pubmed: 26013186
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
J Hepatol. 2022 Mar;76(3):681-693
pubmed: 34801630
Cancer Treat Rev. 2019 Jan;72:28-36
pubmed: 30447470
Hepatol Int. 2021 Jun;15(3):685-694
pubmed: 34043158
Mol Genet Genomics. 2010 Apr;283(4):341-9
pubmed: 20165882
J Hepatol. 2014 Dec;61(6):1287-96
pubmed: 25016222
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255
pubmed: 30285213
J Hepatol. 2021 Oct;75(4):960-974
pubmed: 34256065
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
BMC Cancer. 2018 Feb 14;18(1):188
pubmed: 29444653
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Oncol Res Treat. 2018;41(5):292-297
pubmed: 29705790
Ital J Gastroenterol. 1991 Nov;23(8):494-7
pubmed: 1661196
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Oncotarget. 2016 Oct 4;7(40):65052-65066
pubmed: 27542259
Hepatology. 2015 Jun;61(6):1957-67
pubmed: 25645298